FDA Approves Split-Dosing Regimen for Daratumumab in Patients with Multiple Myeloma

Web Exclusives - FDA Updates, In the News

On February 12, 2019, the US Food and Drug Administration (FDA) granted approval for daratumumab (Darzalex; Janssen), a CD38-directed antibody, to be given in a split-dosing regimen to patients with multiple myeloma (MM). Darzalex is the first and only CD38-directed antibody to receive regulatory approval for the treatment of patients with MM and is the first to be approved for the split-dosing regimen. This new regimen gives patients and healthcare providers the option to split the first dose of Darzalex over the course of 2 consecutive days, which has the benefit of shortening the duration of the first infusion.

“We are pleased that, with this change, patients in the U.S. receiving their first infusion of Darzalex may now have this more flexible dosing options,” stated Jan van de Winkel, chief executive officer of Janssen’s Copenhagen, Denmark–based research partner, Genmab A/S. The US approval follows approvals in December 2018 in the European Union and Canada for the daratumumab initial infusion split-dosing regimen.

The FDA approval of the split-dosing regimen is based on data from the global, multiarm, phase 1b EQUULEUS (MMY1001) clinical trial, which evaluated Darzalex in combination with various treatment regimens in patients with MM. The study investigators reported that, regardless of whether the first dose of Darzalex was administered as a split infusion or as a single infusion, pharmacokinetic concentrations were comparable at the end of weekly dosing; they also observed a similar rate and pattern of infusion reactions.

The safety profile of Darzalex was comparable when administered initially as a split or single dose, and no new safety events were observed with a split first dose. The most frequently reported adverse reactions (incidence ≥20%) in clinical trials were infusion reactions, neutropenia, thrombocytopenia, fatigue, nausea, diarrhea, constipation, vomiting, muscle spasms, arthralgia, back pain, pyrexia, chills, dizziness, insomnia, cough, dyspnea, peripheral edema, peripheral sensory neuropathy, and upper respiratory tract infection.

MM, the second most common hematologic cancer in the United States, is considered incurable, although it is manageable. Approximately 32,110 new cases of MM will be diagnosed in the United States in 2019 (18,130 in men and 13,980 in women) and approximately 12,960 deaths are expected to be attributed to the disease (6990 in men and 5970 in women).

Related Items
FDA News: June 22, 2022, and August 11, 2022.
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in FDA Updates
FDA News: April 1, 2022, and May 27, 2022
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in FDA Updates
FDA NEWS: February 28, 2022 to March 31, 2022
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in FDA Updates
FDA NEWS: January 10, 2022, and January 25, 2022
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in FDA Updates
FDA NEWS: November 29, 2021, and December 15, 2021
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in FDA Updates
FDA NEWS: August 13, 2021 to September 22, 2021
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in FDA Updates
FDA Issues Revised Final Guidance on Biosimilar Development and the BPCI Act
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in FDA Updates, Biosimilars
FDA NEWS: June 30, 2021, and July 26, 2021
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in FDA Updates
FDA NEWS: May 5, 2021 to May 28, 2021
TOP - July 2021 Vol 14, No 4 published on July 20, 2021 in FDA Updates
FDA NEWS: April 13, 2021 to April 23, 2021
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in FDA Updates
Last modified: July 22, 2021